First Post-Market Safety Report on OssDsign Catalyst shows zero percent device related complication rate
Uppsala, November 17, 2022. OssDsign AB (publ.) today announces data from the first post-market safety report of the company's innovative product OssDsign Catalyst, that stimulates bone growth in spinal fusion. The report, which covers the time from product launch in August 2021 until August 31, 2022, did not record any device related complaints nor device related adverse events.OssDsign Catalyst is a nanosynthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. Similar to the body’s own bone mineral structure, the patented nanocrystalline